<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792920</url>
  </required_header>
  <id_info>
    <org_study_id>XIENCE STEMI Registry</org_study_id>
    <nct_id>NCT02792920</nct_id>
  </id_info>
  <brief_title>Multicenter Registry of Very Early and Late Clinical Outcomes to Everolimus-eluting Cobalt-Chromium Stent In Patients With ST Elevation Myocardial Infarction</brief_title>
  <acronym>XIENCE STEMI</acronym>
  <official_title>Multicenter Registry of Very Early and Late Clinical Outcomes to Everolimus-eluting Cobalt-Chromium Stent In Patients With ST Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyogo Brain and Heart Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hyogo Brain and Heart Center</source>
  <brief_summary>
    <textblock>
      To compare early and late clinical outcomes with everolimus-eluting cobalt-chromium stent in&#xD;
      patients with ST-elevation acute myocardial infarction, as well as identify the&#xD;
      characteristics and efficacy of CoCr-EES.&#xD;
&#xD;
      Also, OCT sub-analysis will be conducted&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target vessel failure (TVF)</measure>
    <time_frame>12 months</time_frame>
    <description>Target vessel failure (TVF) at 12 months after CoCr-EES implantation. TVF consists of defined as cardiac death, target vessel-related recurrent myocardial infarction (MI) or Target Lesion Revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MI (QMI and Non-QMI)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any TLR</measure>
    <time_frame>12 months and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Target Vessel Revascularization (TVR)</measure>
    <time_frame>12 months and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE (Cardiac death, MI and TLR)</measure>
    <time_frame>12 months and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite or Probable stent thrombosis</measure>
    <time_frame>12 months and 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>ST-elevation Acute Myocardial Infarction</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>CoCr-EES</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoCr-EES</intervention_name>
    <arm_group_label>CoCr-EES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with STEMI who are able to undergo CoCr-EES implantation.&#xD;
&#xD;
          2. Patients with no history of PCI in the target vessel&#xD;
&#xD;
          3. Patients who are 20 or older at the time of informed consent&#xD;
&#xD;
          4. Patients who provided written informed consent by himself/herself&#xD;
&#xD;
          5. Patients who are judged by their treating physician to be able to undergo PCI with&#xD;
             CoCr-EES&#xD;
&#xD;
          6. Patients for whom thrombus aspiration prior to CoCr-EES implantation can be&#xD;
             recommended&#xD;
&#xD;
          7. Patients who meet all the following vascular inclusion criteria i.Patients with target&#xD;
             lesion in native coronary artery ii.Patients with visual maximum vessel diameter of&#xD;
             the target stent site in target lesion&#xD;
&#xD;
          8. Patients were obtained finally revascularization of TIMI 3 by visual observation in&#xD;
             the target vessel&#xD;
&#xD;
          9. Patients who are able to treat with CoCr-EES the diameter 2.5mm or more and 3.5mm or&#xD;
             less and the length of 8mm or more and 28mm or less.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients participating in the other ongoing registry or clinical study(except&#xD;
             post-marketing surveillance of CoCr-EES), or receiving treatment which may impact on&#xD;
             endpoints of this study.&#xD;
&#xD;
          2. Patients presenting with cardiogenic shock&#xD;
&#xD;
          3. Patients for whom 12-month and 36-month CAG and clinical follow up is considered&#xD;
             difficult (patient's residence should also be taken into account)&#xD;
&#xD;
          4. Patients with responsible lesion in left main trunk&#xD;
&#xD;
          5. Patients with renal insufficiency or with chronic renal failure with serum creatinine&#xD;
             level of 2.0mg/dL or higher at visit&#xD;
&#xD;
          6. Patients on hemodialysis&#xD;
&#xD;
          7. Patients with a known history of adverse drug reactions to aspirin, or clopidogrel or&#xD;
             prasugrel (This may not apply if safety of ticlopidine is confirmed as an alternative&#xD;
             drug.)&#xD;
&#xD;
          8. Patients who are below the age of 20&#xD;
&#xD;
          9. Women who were positive in pregnancy test or wish to become pregnant during study&#xD;
             duration&#xD;
&#xD;
         10. Patients who newly developed AMI attributable to the prior stented site&#xD;
&#xD;
         11. Patients with a known history of allergy to drug, polymer, metal, and other materials&#xD;
             used in CoCr-EES&#xD;
&#xD;
         12. Patients diagnosed with hepatic insufficiency&#xD;
&#xD;
         13. Patients with target lesion in saphenous vein graft&#xD;
&#xD;
         14. Patients with active malignant tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yoshinori Yasaka, M.D.</last_name>
    <phone>+81-79-293-3131</phone>
    <email>yoshiysk@yahoo.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hyogo Brain and Heart Center</name>
      <address>
        <city>Himeji, Hyogo,</city>
        <zip>6700981</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshinori Yasaka, M.D.</last_name>
      <phone>+81-79-293-3131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Higashi Takarazuka Sato Hospital</name>
      <address>
        <city>Takarazuka, Hyogo</city>
        <zip>6650873</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoru Otsuji, M.D.</last_name>
      <phone>+81-797-88-2200</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

